Research
Remedy: Back in the game
By Atte Riikola
The investor sentiment around Remedy has recently soured, where we believe the key factors are the write-down of Vanguard’s development expenditure and the postponement of the financial statements based on publishing contract negotiations. In addition, uncertainty about Alan Wake 2’s commercial success causes uncertainty around the stock. We believe that the content of the publishing contract and the sales figures of AW2 will be clarified in connection with the financial statements (3/20) at the latest, and with the decreased valuation we feel Remedy's long-term potential looks interesting again.
Remedy Entertainment is a game developer. Its operations are primarily focused on the development of action games, with a particular focus on 3D technology. Examples of games that the company has developed include several different versions of Alan Wake, Max Payne, and Control. Remedy also develops its own game engine and tooling technology that powers many of its games. The company was founded in 1995 and is headquartered in Espoo, Finland.
Read more on company pageKey Estimate Figures12.02.2024
| 2022 | 23e | 24e | |
|---|---|---|---|
| Revenue | 43.6 | 33.9 | 67.2 |
| growth-% | -2.5 % | -22.2 % | 98.3 % |
| EBIT (adj.) | -0.6 | -28.7 | 9.9 |
| EBIT-% (adj.) | -1.3 % | -84.6 % | 14.8 % |
| EPS (adj.) | -0.13 | -1.71 | 0.59 |
| Dividend | 0.10 | 0.10 | 0.10 |
| Dividend % | 0.5 % | 0.7 % | 0.7 % |
| P/E (adj.) | neg. | neg. | 25.7 |
| EV/EBITDA | 126.5 | neg. | 11.7 |
Forum discussions
